Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin
Drug ID BADD_D01455
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Marketing Status approved; investigational
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D08218
MeSH ID D000077551
PubChem ID 477468
TTD Drug ID D06TOE
NDC Product Code 16714-301; 70710-1725; 60505-6120; 70771-1683; 60505-6119; 70771-1684; 42023-229; 16714-164; 70710-1724; 42023-230
UNII R10H71BSWG
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H71N9O23S
CAS Registry Number 235114-32-6
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(C C(=O)N)O)C)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.000150%
Immune system disorder10.02.01.001---
Infection11.01.08.002---
Injection site extravasation08.02.03.002; 12.07.03.0020.001017%-
Injection site pain08.02.03.010; 12.07.03.011---
Injection site reaction08.02.03.014; 12.07.03.015--
Injection site thrombosis08.02.03.028; 12.07.03.028; 24.01.01.023---
Insomnia17.15.03.002; 19.02.01.002--
Intestinal perforation07.04.06.0020.000150%-
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Leukopenia01.02.02.0010.000224%-
Liver disorder09.01.08.001---
Liver function test abnormal13.03.04.030---
Lymphopenia01.02.02.002---
Mucosal inflammation08.01.06.002---
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001---
Nephropathy20.05.03.001---
Nervous system disorder17.02.10.001---
Neutropenia01.02.03.0040.000150%-
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oliguria20.01.03.004---
Osteolysis14.04.04.006; 15.02.03.0080.000150%-
Palpitations02.11.04.012--
Pancytopenia01.03.03.0030.000150%-
Pericardial effusion02.06.01.002--
Phlebitis12.02.01.002; 24.12.03.004--
Pneumonia11.01.09.003; 22.07.01.003---
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages